A phase II, multicenter, randomized, assessor-blinded, active-comparator, dose-finding study to evaluate AS900672 [recombinant follicle stimulating hormone] enriched versus follitropin alfa (Gonal-f) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology (ART).

Trial Profile

A phase II, multicenter, randomized, assessor-blinded, active-comparator, dose-finding study to evaluate AS900672 [recombinant follicle stimulating hormone] enriched versus follitropin alfa (Gonal-f) in stimulating multiple follicular development in infertile women undergoing assisted reproductive technology (ART).

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Recombinant follicle-stimulating hormone (Primary) ; Follitropin alfa
  • Indications Infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jul 2012 Primary outcome added as reported in the European Clinical Trials Database record.
    • 04 Jul 2012 Merck Serono and Serono Europe added as associations as reported in the European Clinical Trials Database record.
    • 25 May 2012 Actual patient number is 522 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top